Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Rhea-AI Summary

Aditxt (NASDAQ: ADTX) announced a significant milestone in its acquisition plans for Appili Therapeutics (TSX: APLI; OTCPink: APLIF). At a special meeting, Appili's shareholders voted overwhelmingly in favor of a plan of arrangement that would allow Aditxt to acquire all issued and outstanding Class A common shares of Appili. This development marks a important step forward in Aditxt's strategy to expand its healthcare innovation platform.

Positive

• Shareholders' strong approval indicates high confidence in the acquisition
• Strategic expansion of Aditxt's healthcare innovation portfolio through acquisition

Negative

• None.

Insights

Financial Analyst

The shareholder approval marks a important milestone in Aditxt's acquisition of Appili Therapeutics, though several key details remain undisclosed. For a micro-cap company like Aditxt with a market cap of just $4.2 million, this acquisition could significantly impact its business model and financial structure. The overwhelming shareholder support suggests confidence in the deal's potential value, but investors should note that the terms, including purchase price and financing arrangements, haven't been publicly detailed. Critical considerations include Appili's infectious disease pipeline and how this acquisition aligns with Aditxt's strategy of accelerating health innovations.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information and results of Appili’s special meeting of shareholders, please visit this link.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. Appili aims to strategically develop a pipeline of novel therapies to prevent deaths and improve lives by systematically identifying urgent infections with unmet needs. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a severe biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Appili is at the epicenter of the global fight against infection, led by a proven management team. For more information, visit www.AppiliTherapeutics.com.

About Aditxt, Inc.

Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com.

Follow us on:

LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107621389/en/

Aditxt, Inc.

Investors:

Jeff Ramson, PCG Advisory, Inc.

T: 646-863-6893

Jramson@pcgadvisory.com

Corporate Communications:

Mary O’Brien

Mobrien@aditxt.com

Source: Aditxt, Inc.

FAQ

What was the outcome of Appili Therapeutics' special shareholder meeting regarding ADTX acquisition?

Appili Therapeutics' shareholders voted overwhelmingly in favor of the plan of arrangement for Aditxt (ADTX) to acquire all issued and outstanding Class A common shares of the company.

What is the purpose of ADTX's acquisition of Appili Therapeutics?

The acquisition aligns with Aditxt's mission as a social innovation platform focused on accelerating promising health innovations, representing a strategic expansion of their healthcare portfolio.

Which stock exchanges are Aditxt (ADTX) and Appili Therapeutics listed on?

Aditxt is listed on NASDAQ under the symbol ADTX, while Appili Therapeutics is listed on the Toronto Stock Exchange (TSX: APLI) and trades on OTC Pink (APLIF).